E T Middleton1, S A Steel, M Aye, S M Doherty. 1. Centre for Metabolic Bone Disease, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull HU3 2RW, UK. etmiddleton@doctors.org.uk
Abstract
UNLABELLED: Many osteoporotic women prescribed strontium ranelate have previously received bisphosphonates. Prior bisphosphonate use blunted the spinal bone mineral density (BMD) response for 6 months. Hip BMD was blunted to a degree for 2 years, although there was an overall increase in hip BMD in contrast to the heel where BMD did not increase. INTRODUCTION: Many osteoporotic women commenced on strontium ranelate have already received treatment with bisphosphonates. This study investigates whether prior bisphosphonate use impairs the subsequent therapeutic response to strontium ranelate. METHODS: Women were recruited who were either bisphosphonate naïve or currently receiving a bisphosphonate. All women received strontium ranelate and were followed up for 2 years. RESULTS:One hundred and twenty women were recruited. After 2 years, the bisphosphonate-naïve group had significant BMD increases of 8.9%, 6.0% and 6.4% at the spine, hip and heel, respectively. In the prior bisphosphonate group, BMD increased significantly at the spine (4.0%) and hip (2.5%) but not at the heel. At all time points at all sites, the BMD increase was greater in the bisphosphonate-naïve group. BMD at the spine did not increase during the first 6 months in the prior bisphosphonate group but then increased in parallel with the bisphosphonate-naïve group. In contrast, the difference between the two groups in hip BMD continued to increase throughout the 2 years. P1NP was suppressed in the prior bisphosphonate group for the first 6 months. CONCLUSIONS: After bisphosphonate exposure, the BMD response to strontium ranelate is blunted for only 6 months at the spine. At the hip, a degree of blunting was observed over 2 years, although there was an overall increase in hip BMD in contrast to the heel where no increase in BMD was observed.
RCT Entities:
UNLABELLED: Many osteoporoticwomen prescribed strontium ranelate have previously received bisphosphonates. Prior bisphosphonate use blunted the spinal bone mineral density (BMD) response for 6 months. Hip BMD was blunted to a degree for 2 years, although there was an overall increase in hip BMD in contrast to the heel where BMD did not increase. INTRODUCTION: Many osteoporoticwomen commenced on strontium ranelate have already received treatment with bisphosphonates. This study investigates whether prior bisphosphonate use impairs the subsequent therapeutic response to strontium ranelate. METHODS:Women were recruited who were either bisphosphonate naïve or currently receiving a bisphosphonate. All women received strontium ranelate and were followed up for 2 years. RESULTS: One hundred and twenty women were recruited. After 2 years, the bisphosphonate-naïve group had significant BMD increases of 8.9%, 6.0% and 6.4% at the spine, hip and heel, respectively. In the prior bisphosphonate group, BMD increased significantly at the spine (4.0%) and hip (2.5%) but not at the heel. At all time points at all sites, the BMD increase was greater in the bisphosphonate-naïve group. BMD at the spine did not increase during the first 6 months in the prior bisphosphonate group but then increased in parallel with the bisphosphonate-naïve group. In contrast, the difference between the two groups in hip BMD continued to increase throughout the 2 years. P1NP was suppressed in the prior bisphosphonate group for the first 6 months. CONCLUSIONS: After bisphosphonate exposure, the BMD response to strontium ranelate is blunted for only 6 months at the spine. At the hip, a degree of blunting was observed over 2 years, although there was an overall increase in hip BMD in contrast to the heel where no increase in BMD was observed.
Authors: Gary P Liney; Clare P Bernard; David J Manton; Lindsay W Turnbull; Chris M Langton Journal: J Magn Reson Imaging Date: 2007-09 Impact factor: 4.813
Authors: O Bruyère; J Collette; R Rizzoli; C Decock; S Ortolani; C Cormier; J Detilleux; J-Y Reginster Journal: Osteoporos Int Date: 2009-10-08 Impact factor: 4.507
Authors: Barbara M Obermayer-Pietsch; Fernando Marin; Eugene V McCloskey; Peyman Hadji; Jordi Farrerons; Steven Boonen; Maurice Audran; Clare Barker; Athanasios D Anastasilakis; William D Fraser; Thomas Nickelsen Journal: J Bone Miner Res Date: 2008-10 Impact factor: 6.741
Authors: Robert R Recker; Fernando Marin; Sophia Ish-Shalom; Rüdiger Möricke; Federico Hawkins; Georgios Kapetanos; María P de la Peña; Jörn Kekow; Jordi Farrerons; Beatriz Sanz; Heide Oertel; Jan Stepan Journal: J Bone Miner Res Date: 2009-08 Impact factor: 6.741
Authors: S P Nielsen; D Slosman; O H Sørensen; B Basse-Cathalinat; P De Cassin; C R Roux; P J Meunier Journal: J Clin Densitom Date: 1999 Impact factor: 2.963
Authors: Lucas R Brun; Ana M Galich; Eduardo Vega; Helena Salerni; Laura Maffei; Valeria Premrou; Pablo R Costanzo; Marcelo A Sarli; Paula Rey; María S Larroudé; María S Moggia; María L Brance; Ariel Sánchez Journal: Springerplus Date: 2014-11-18
Authors: F Vescini; R Attanasio; A Balestrieri; F Bandeira; S Bonadonna; V Camozzi; S Cassibba; R Cesareo; I Chiodini; C Maria Francucci; L Gianotti; F Grimaldi; R Guglielmi; B Madeo; C Marcocci; A Palermo; A Scillitani; E Vignali; V Rochira; M Zini Journal: J Endocrinol Invest Date: 2016-03-11 Impact factor: 4.256